Background: Inflammation has been reported to drive cancer-related fatigue (CRF). As both obesity and chemotherapy promote inflammatory responses, obese cancer patients may be at risk of more severe CRF, especially when receiving chemotherapy.

Methods: We analysed data of 333 colon cancer patients from four hospitals in the Netherlands (data derived from the PROCORE study). Fatigue was assessed with the general fatigue subscale of the Multidimensional Fatigue Inventory at four timepoints: at inclusion (T1), 4 weeks after surgery (T2), and 1 (T3) and 2 years (T4) after diagnosis. Linear mixed-effects models were applied to evaluate the interaction between chemotherapy and body mass index (BMI) on the trajectory of fatigue.

Results: The two-way interactions between time and chemotherapy (p = 0.047) and between time and BMI on fatigue (p = 0.041) were significant. Patients scheduled for chemotherapy reported more fatigue during the treatment phase, while patients not treated with chemotherapy showed a stable trajectory. Obese patients reported more fatigue at follow-up compared to patients with a healthy BMI. The three-way interaction between time, chemotherapy and BMI was not significant (p = 0.39). However, obese chemotherapy-treated patients reported the highest fatigue 2 years after treatment (12.8, 95% CI: 10.6-14.9). Their mean fatigue score was higher compared to baseline (9.2, 95% CI: 7.3-11.0, p < 0.001) and obese patients not treated with chemotherapy (9.6, 95% CI: 7.0-12.2, p = 0.02). Moreover, this group reported more fatigue compared to healthy (8.1, 95% CI: 5.5-10.9, p < 0.001) and overweight (9.7, 95% CI: 7.2-12.3, p = 0.019) chemotherapy-treated patients.

Conclusion: This study indicates that chemotherapy and BMI both influence long-term fatigue in colon cancer patients. Proactive monitoring for CRF and lifestyle interventions may be needed for chemotherapy-treated patients with a high BMI.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11702450PMC
http://dx.doi.org/10.1002/cam4.70536DOI Listing

Publication Analysis

Top Keywords

cancer patients
12
fatigue
10
chemotherapy body
8
body mass
8
cancer-related fatigue
8
colon cancer
8
patients
8
time chemotherapy
8
reported fatigue
8
patients reported
8

Similar Publications

Acute leukemia (AL) affects patients' well-being and inflicts substantial symptom burden. We evaluated palliative care needs and symptom burden in adult patients with AL from diagnosis through fourth week of induction chemotherapy. Newly diagnosed adult patients with AL scheduled for curative-intent treatments, prospectively completed Functional Assessment of Cancer Therapy-Leukemia questionnaire at diagnosis and postinduction therapy.

View Article and Find Full Text PDF

Importance: Three similar phase 3 randomized clinical trials have investigated PD-1/PD-L1 (programmed cell death 1 protein/programmed cell death 1 ligand 1) inhibitors in combination with platinum-based chemotherapy vs chemotherapy alone as first-line treatment for advanced urothelial carcinoma (IMvigor130, atezolizumab; KEYNOTE-361, pembrolizumab; and CheckMate901, nivolumab). Only CheckMate901 reported overall survival (OS) benefit for the combination. The reason for these inconsistent results is unclear.

View Article and Find Full Text PDF

Immunomodulatory drug (IMiD) resistance is a key clinical challenge in myeloma treatment. Previous data suggests almost one third of myeloma patients acquire mutations in the key IMiD effector cereblon by the time they are pomalidomide refractory. Some events, including stop codons/frameshift mutations and copy loss, having clearly explicable effects on cereblon function.

View Article and Find Full Text PDF

Stemness-associated cell states are linked to chemotherapy resistance in AML. We uncovered a direct mechanistic link between expression of the stem cell transcription factor GATA2 and drug resistance. The GATA-binding protein 2 (GATA2) plays a central role in blood stem cell generation and maintenance.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!